Tinengotinib

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Tinengotinib is an investigational new drug that is being evaluated for the treatment of cancer. It is an multi-kinase inhibitor designed to target a range of kinases involved in cancer cell proliferation, angiogenesis, and immune response modulation. Specifically, it inhibits fibroblast growth factor receptors (FGFRs) 1–3, janus kinase (JAK) 1/2, vascular endothelial growth factor receptors (VEGFRs), and aurora kinases A/B.

Tinengotinib is an investigational new drug that is being evaluated for the treatment of cancer. It is an multi-kinase inhibitor designed to target a range of kinases involved in cancer cell proliferation, angiogenesis, and immune response modulation. Specifically, it inhibits fibroblast growth factor receptors (FGFRs) 1–3, janus kinase (JAK) 1/2, vascular endothelial growth factor receptors (VEGFRs), and aurora kinases A/B.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1355707240 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.